Vapotherm, Inc.

Equities

VAPO

US9221073052

Advanced Medical Equipment & Technology

Market Closed - OTC Markets Other stock markets 03:20:41 2024-05-23 pm EDT			5-day change	1st Jan Change
0.86 ^USD	+2.44%		0.00%	-14.00%

May. 09	Vapotherm, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 01	Vapotherm, Inc. Enters into Amendment No. 7 to Loan and Security Agreement with SLR Investment Corp	CI

Vapotherm, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 09, 2024 at 04:10 pm EDT

Vapotherm, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 19.13 million compared to USD 17.73 million a year ago. Net loss was USD 14.84 million compared to USD 18.09 million a year ago.

Basic loss per share from continuing operations was USD 2.31 compared to USD 3.56 a year ago. Diluted loss per share from continuing operations was USD 2.31 compared to USD 3.56 a year ago.

Latest news about Vapotherm, Inc.

Vapotherm, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Vapotherm, Inc. Enters into Amendment No. 7 to Loan and Security Agreement with SLR Investment Corp	Apr. 01	CI
Vapotherm, Inc. to Unveil Access365 Home Ventilation Solution at MEDTRADE	Mar. 15	CI
Vapotherm, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Vapotherm, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Vapotherm, Inc.(OTCPK:VAPO) dropped from S&P TMI Index	Dec. 20	CI
Vapotherm Says NYSE Suspends Its Shares' Trading Due to Non-Compliance With Market Capitalization Listing Rule	Dec. 15	MT
Top Premarket Decliners	Dec. 11	MT
Transcript : Vapotherm, Inc., Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Vapotherm, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Earnings Flash (VAPO) VAPOTHERM Posts Q3 Revenue $15.2M, vs. Street Est of $16.7M	Nov. 08	MT
Vapotherm, Inc. Revises Revenue Guidance for the Full Year 2023	Nov. 08	CI
Vapotherm, Inc. Reiterates Revenue Guidance for the Full Year 2023	23-10-02	CI
Vapotherm, Inc. and its Chief Commercial Officer, Gregoire Ramade, Mutually Agreed to an Amicable Separation of Employment, Effective October 31, 2023	23-10-02	CI
Vapotherm Announces Presentation of an Investigator-Initiated Clinical Trial, 'High Flow Humidified Oxygen as an Early Intervention in Children with Acute Severe Asthma - a Feasibility Randomized Controlled Trial' at the European Respiratory Society International Congress 2023	23-09-25	CI
Vapotherm Shares Rise After Chief Executive Joseph Army Executes Stock Purchase	23-09-11	MT
Insider Buy: Vapotherm	23-09-11	MT
Insider Buy: Vapotherm	23-08-31	MT
Insider Buy: Vapotherm	23-08-22	MT
Insider Buy: Vapotherm	23-08-15	MT
Transcript : Vapotherm, Inc., Q2 2023 Earnings Call, Aug 08, 2023	23-08-08
Vapotherm, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Earnings Flash (VAPO) VAPOTHERM Reports Q2 Revenue $16M, vs. Street Est of $17M	23-08-08	MT
Vapotherm, Inc. Revises Earnings Guidance for Fiscal 2023	23-08-08	CI
Vapotherm, Inc.(NYSE:VAPO) dropped from Russell Microcap Index	23-06-23	CI

Chart Vapotherm, Inc.

Duration

Period

More charts

Company Profile

Vapotherm, Inc. is a developer and manufacturer of advanced respiratory technology. It develops non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. It is focused on the care of patients suffering from respiratory distress, whether associated with lung diseases, such as chronic obstructive pulmonary disease, congestive heart failure, pneumonia, asthma, and COVID-19 or other systemic conditions. Its device solutions are focused on High Velocity Nasal Insufflation, which delivers non-invasive ventilatory support to patients by providing heated, humidified, oxygenated air at high velocities through a small-bore nasal interface, and on closed loop control systems, such as its Oxygen Assist Module, designed to automatically maintain a patients pulse oxygen saturation levels within a specified range for a defined period of time. Its digital solutions are focused on remote patient monitoring, using algorithms to predict respiratory episodes.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
VAPOTHERM, INC.	-14.00%	5.35M
THERMO FISHER SCIENTIFIC	+10.22%	223B
DANAHER CORPORATION	+12.99%	194B
INTUITIVE SURGICAL, INC.	+18.09%	141B
BOSTON SCIENTIFIC CORPORATION	+28.66%	109B
SIEMENS HEALTHINEERS AG	+1.48%	64.85B
EDWARDS LIFESCIENCES CORPORATION	+14.70%	52.7B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+6.68%	51.77B
AGILENT TECHNOLOGIES, INC.	+8.29%	44.12B
GE HEALTHCARE TECHNOLOGIES INC.	+2.60%	36.21B

Other Advanced Medical Equipment & Technology

Vapotherm, Inc.

Equities

VAPO

US9221073052

Advanced Medical Equipment & Technology

Vapotherm, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

Latest news about Vapotherm, Inc.

Chart Vapotherm, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Advanced Medical Equipment & Technology